RUNX2 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, compared with CML-oxLDL-Abs group, the treatment with anti-cbfa1 antibody could inhibite ALP activity by 54.5% (297.2 ± 26.5 versus 652.8 ± 63.3 U/mg, P < 0.001) and reduced intercellular calcium deposition by 49.0% (3.63 ± 0.33 versus 7.12 ± 0.81 μmol/mg, P < 0.001).